X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 29.9 12.2 245.1% View Chart
P/BV x 2.9 3.2 90.9% View Chart
Dividend Yield % 0.9 0.4 246.1%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
GLENMARK PHARMA
Mar-17
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,397993 342.1%   
Low Rs2,560729 351.0%   
Sales per share (Unadj.) Rs856.5325.5 263.1%  
Earnings per share (Unadj.) Rs78.039.3 198.4%  
Cash flow per share (Unadj.) Rs139.948.7 287.5%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.70.2 289.1%  
Book value per share (Unadj.) Rs739.8159.2 464.7%  
Shares outstanding (eoy) m165.74282.17 58.7%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x3.52.6 131.4%   
Avg P/E ratio x38.221.9 174.3%  
P/CF ratio (eoy) x21.317.7 120.3%  
Price / Book Value ratio x4.05.4 74.4%  
Dividend payout %25.75.1 504.0%   
Avg Mkt Cap Rs m493,632242,991 203.1%   
No. of employees `00022.713.0 174.9%   
Total wages/salary Rs m31,06816,408 189.3%   
Avg. sales/employee Rs Th6,259.07,083.9 88.4%   
Avg. wages/employee Rs Th1,369.81,265.4 108.3%   
Avg. net profit/employee Rs Th569.7855.1 66.6%   
INCOME DATA
Net Sales Rs m141,96191,857 154.5%  
Other income Rs m1,715374 459.0%   
Total revenues Rs m143,67692,230 155.8%   
Gross profit Rs m24,72220,367 121.4%  
Depreciation Rs m10,2662,644 388.3%   
Interest Rs m6342,373 26.7%   
Profit before tax Rs m15,53715,724 98.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2,9653,827 77.5%   
Profit after tax Rs m12,92111,088 116.5%  
Gross profit margin %17.422.2 78.5%  
Effective tax rate %19.124.3 78.4%   
Net profit margin %9.112.1 75.4%  
BALANCE SHEET DATA
Current assets Rs m96,83768,746 140.9%   
Current liabilities Rs m84,19927,027 311.5%   
Net working cap to sales %8.945.4 19.6%  
Current ratio x1.22.5 45.2%  
Inventory Days Days7385 86.3%  
Debtors Days Days9896 102.2%  
Net fixed assets Rs m102,55224,132 425.0%   
Share capital Rs m829282 293.8%   
"Free" reserves Rs m121,79244,643 272.8%   
Net worth Rs m122,62144,925 272.9%   
Long term debt Rs m5,44945,363 12.0%   
Total assets Rs m218,165117,639 185.5%  
Interest coverage x25.57.6 334.5%   
Debt to equity ratio x01.0 4.4%  
Sales to assets ratio x0.70.8 83.3%   
Return on assets %6.211.4 54.3%  
Return on equity %10.524.7 42.7%  
Return on capital %12.919.1 67.4%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Exports (fob) Rs m77,520NA-   
Imports (cif) Rs m13,274NA-   
Fx inflow Rs m81,67056,152 145.4%   
Fx outflow Rs m26,3558,084 326.0%   
Net fx Rs m55,31548,068 115.1%   
CASH FLOW
From Operations Rs m21,4446,574 326.2%  
From Investments Rs m-18,404-7,124 258.4%  
From Financial Activity Rs m-3,6925,432 -68.0%  
Net Cashflow Rs m-1,1441,992 -57.4%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS